Haw Par Corporation Limited

H02

SG1D25001158

Pharmaceuticals

Delayed Singapore S.E. Other stock markets 03:04:34 2024-05-03 am EDT			5-day change	1st Jan Change
9.67 ^SGD	-1.83%		-2.03%	-0.82%

Apr. 23	Haw Par Corporation Limited Announces Board Appointments	CI
Feb. 26	Haw Par Corporation Limited Proposes One-Tier Tax-Exempt Second and Final Dividend for the Financial Year Ended 31 December 2023, Payable on 21 May 2024	CI

Haw Par Corporation Limited Announces Demise of Wee Cho Yaw as Chairman, Non-Executive and Non-Independent Director

February 03, 2024 at 06:22 am EST

Haw Par Corporation Limited announced demise of Wee Cho Yaw as Chairman, Non-Executive and Non-Independent Director. Dr Wee Cho Yaw is a substantial shareholder of the Company, the father of both Mr. Wee Ee Lim, President and Chief Executive Officer and Non-Independent Director of the Company and Mr. Wee Ee Chao, the Deputy Chairman, Non-Executive and Non-Independent Director of the Company. Dr Wee Cho Yaw passed away on 3 February 2024.

Latest news about Haw Par Corporation Limited

Haw Par Corporation Limited Announces Board Appointments	Apr. 23	CI
Haw Par Corporation Limited Proposes One-Tier Tax-Exempt Second and Final Dividend for the Financial Year Ended 31 December 2023, Payable on 21 May 2024	Feb. 26	CI
Haw Par Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Haw Par Corporation Limited Announces Retirement of Gn Hiang Meng as Non-Executive and Independent Director	Feb. 26	CI
Haw Par Corporation Limited Appoints Lee Huey Jee Jenny as Non-Executive and Independent Director	Feb. 26	CI
Haw Par Corporation Limited Announces Appointment of Wee Ee Chao as Chairman	Feb. 26	CI
Haw Par Chairman Dies	Feb. 04	MT
Haw Par Corporation Limited Announces Demise of Wee Cho Yaw as Chairman, Non-Executive and Non-Independent Director	Feb. 03	CI
Haw Par Corporation Limited(SGX:H02) added to S&P Global BMI Index	23-09-18	CI
Haw Par's Net Profit Jumps 35% in H1	23-08-14	MT
Haw Par Corporation Limited Declares First and Interim One-Tier Tax Exempt Dividend for the Financial Year Ending 31 December 2023, Payable on 7 September 2023	23-08-11	CI
Haw Par Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-11	CI
Haw Par Corporation Limited Approves Second and Final Tax-Exempt Dividend for the Financial Year Ended December 31, 2022	23-05-23	CI
Haw Par Corporation Limited Announces Changes in Composition of Board Committees	23-04-25	CI
Haw Par Posts Higher H2 Profit, Revenue	23-02-23	MT
Haw Par Corporation Limited Proposes One-Tier Tax-Exempt Second and Final Dividend for the Financial Year Ended 31 December 2022, Payable on 24 May 2023	23-02-23	CI
Haw Par Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Haw Par Corporation Limited(SGX:H02) dropped from S&P Global BMI Index	22-09-19	CI
Haw Par Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-10	CI
Haw Par Corporation Limited Announces First Interim Cash Dividend, Payable on 2 September 2022	22-08-10	CI
Haw Par Corporation Limited Announces Appointment of Chiew Kun Long, Alvin as Company Secretary	22-05-17	CI
Haw Par Corporation Limited Approves to Declare One-Tier Tax-Exempt Second & Final Dividend for Fiscal Year 2021	22-04-27	CI
Haw Par Corporation Limited Announces Resignation of Lee Kay Swee as Company Secretary	22-03-17	CI
Haw Par's Net Profit Nearly Doubles in H2 2021 as Revenue Zooms 150%	22-02-28	MT
Haw Par Corporation Limited Appoints Chow Say Suan to Member of Investment Committee	22-02-25	CI

Chart Haw Par Corporation Limited

Duration

Period

More charts

Company Profile

Haw Par Corporation Limited is a Singapore-based holding company. The principal activities of the Company are licensing of the Tiger trademarks and owning and holding investments for the long-term. Its segments include Healthcare products, Investments and Others. The Company's Healthcare products segment is engaged in manufacturing and distributing topical analgesic products under the Tiger Balm and Kwan Loong brand. Its Investments segment is engaged in long term investing activities, mainly in quoted securities in Asia. The Company's Others segment includes property division, which owns and leases out several investment properties in Asia, and leisure division, which provides family and tourist-oriented leisure activities in the form of oceanariums. Its Tiger Balm brand products include Tiger Balm White Ointment, Tiger Balm Muscle Rub, Tiger Balm Back Pain Patch and Tiger Balm Muscle Rub. Its Kwan Loong brand products include Kwan Loong Medicated and Oil Kwan Loong Refresher.

Sector

Pharmaceuticals

Calendar

2024-05-02 - Final dividend

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HAW PAR CORPORATION LIMITED	-0.82%	1.61B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.40%	43.67B
OTSUKA HOLDINGS CO., LTD.	+20.67%	22.51B
SANDOZ GROUP AG	+12.12%	14.6B
CIPLA LIMITED	+14.30%	13.74B
ZYDUS LIFESCIENCES LIMITED	+44.34%	11.91B
ONO PHARMACEUTICAL CO., LTD.	-8.37%	7.04B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.42B